Clinical trials
Cancer Risk clinical trials
Below are recruiting cancer risk clinical trials, each written for real people, not researchers. We’re tracking 717 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05761093Recruiting
Share your treatment preferences for metastatic prostate cancer
This study asks people with metastatic prostate cancer and their doctors about what benefits and risks matter most when choosing treatment. Your answers can help improve how treatment options are discussed in Hong Kong.
ShatinAges 18 years+ - NCT05920863RecruitingPhase 2
Lenvatinib, immunotherapy, plus liver artery treatment before surgery
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hangzhou, ZhejiangAges 18–75 - NCT07053059RecruitingPhase 2
CAR T-cell therapy to prevent relapse in high-risk B-cell ALL
This trial tests a new CAR T-cell therapy (obecabtagene autoleucel) given as a consolidation treatment after initial remission to prevent relapse in people with high-risk B-cell ALL. It's for patients who have achieved first remission but still have high-risk features in their leukemia.
Houston, TexasAges 18 years+ - NCT07556562Recruiting
Early ovarian cancer detection through Pap test DNA analysis
This study tests whether DNA found in routine Pap smears can help detect ovarian cancer early in people at high genetic risk. Participants have inherited gene mutations that increase ovarian cancer risk and are considering preventive surgery.
Roma, RomaAges 18 years+ - NCT06797635RecruitingPhase 2
Study of Patritumab Deruxtecan and Pembrolizumab for High-Risk Early Breast Cancer
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
Santa Monica, CaliforniaAges 18 years+ - NCT06614647Recruiting
Digital follow-up for colorectal cancer survivors
This trial tests a smartphone-based follow-up program for people who have been treated for early-stage colorectal cancer. The goal is to see if a digital, need-based care guide can replace standard follow-up visits.
Herning, Central JutlandAges 18 years+ - NCT06369610RecruitingPhase 2
Less hormone therapy with radiation for prostate cancer
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06057948RecruitingPhase 2
Vaccine with beta-glucan for high-risk neuroblastoma
This trial tests a vaccine combined with a substance called beta-glucan to help the immune system recognize and fight neuroblastoma cells. It is for children who have already completed treatment for high-risk neuroblastoma and are now in remission.
Basking Ridge, New JerseyAges Any age - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after bone marrow transplant for high-risk blood cancers
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
Bethesda, MarylandAges 12–120 - NCT05512481RecruitingPhase 2
Study combination treatment before surgery for high-risk acral melanoma
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
Beijing, Beijing MunicipalityAges 18–75 - NCT06594445RecruitingPhase 1
GTB-3650 TriKE for high-risk MDS and relapsed AML
This trial tests a new immunotherapy called GTB-3650 TriKE for people with high-risk MDS or AML that has come back or not responded to treatment. It aims to boost your immune system to fight the cancer.
Minneapolis, MinnesotaAges 18 years+ - NCT06637267Recruiting
Testing a new blood test to improve prostate cancer risk assessment
This trial is testing a new blood test (Proclarix) to see if it can better predict prostate cancer risk in men who are already scheduled for an MRI and prostate biopsy. The goal is to improve how doctors decide who needs a biopsy.
Aarau, Canton of AargauAges 45–80 - NCT07250477RecruitingPhase 2
Guided immunotherapy for advanced lung cancer
This trial tests whether using a blood test to guide treatment can improve outcomes for people with advanced non-small cell lung cancer who are starting immunotherapy for the first time. Participants will receive standard immunotherapy tailored to their individual risk profile.
Sacramento, CaliforniaAges 18 years+ - NCT03408353Recruiting
MERIT study uses mammogram and blood tests to assess breast cancer risk
This study looks for signs in blood samples and imaging that may help estimate breast cancer risk earlier. You would do a mammogram and give blood at the start and then again at yearly follow-up visits.
Houston, TexasAges 25–80 - NCT06093061RecruitingPhase 2
Maintenance therapy for high-risk nasopharyngeal cancer
This trial tests a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and capecitabine (a chemo pill taken daily)—as maintenance therapy after initial chemotherapy for high-risk nasopharyngeal cancer. The goal is to see if this approach can lower the chance of cancer coming back.
SingaporeAges 21–99 - NCT06341933Recruiting
Kidney risk after lung cancer surgery (VATS)
This study looks at why some people develop kidney problems after lung cancer surgery using small incisions (VATS). By tracking your recovery, the doctors hope to find ways to protect your kidneys during and after surgery.
Ankara, KeçiörenAges 18–65 - NCT06353321Recruiting
PSMA-PET imaging for guiding radiation therapy in prostate cancer
This study tests a new way to use a PSMA-PET scan (a special imaging test that finds prostate cancer cells) to guide a type of radiation treatment called BgRT. It is for men with prostate cancer who are already getting a PSMA-PET scan as part of their regular care.
Dallas, TexasAges Any age - NCT07614594Recruiting
Urine Test to Detect Bladder and Kidney Cancer
This study tests whether a simple urine test can accurately identify cancer in the bladder, ureters (tubes between kidneys and bladder), or renal pelvis (part of the kidney). You would provide urine samples before your planned surgery, and researchers will compare the urine test results to your actual tissue diagnosis after surgery.
Zhengzhou, HenanAges 18 years+ - NCT07445048RecruitingPhase 3
Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
ShanghaiAges 18 years+ - NCT07077447Recruiting
Study on cancer in the upper urinary tract
This trial is for people diagnosed with a rare type of cancer in the upper urinary tract (UTUC). Researchers hope to learn more about this condition and find better ways to treat it.
Aarhus NAges 18 years+ - NCT06666192Recruiting
OSU Community Cancer Screening Program
This program aims to make cancer screening easier for people in certain neighborhoods near Ohio State University clinics. It works with clinics, healthcare providers, and patients to improve access to preventive care.
Columbus, OhioAges Any age - NCT04031677RecruitingPhase 3
Surgery with or without chemotherapy for high-risk retroperitoneal sarcoma
This trial studies whether adding chemotherapy before surgery helps people with high-risk retroperitoneal (abdominal-area) leiomyosarcoma or liposarcoma. The goal is to improve outcomes while comparing surgery alone versus surgery plus neoadjuvant chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT06170710RecruitingPhase 2
Immunotherapy after chemoradiation for high-risk head and neck cancer
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Beijing, Beijing MunicipalityAges 18–70 - NCT06649058RecruitingPhase 2
Study on combining drugs and radiation for brain metastases
This trial is for people with cancer that has spread to the brain (brain metastases). It tests a new approach where you start a systemic therapy (drugs that travel through your body) and later add focused radiation to the brain tumors, instead of treating them right away. The goal is to see if this sequence works well and avoids unnecessary side effects.
Houston, TexasAges 18 years+
Hear when a new Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer risk?
- Yes. Clin2 currently lists 717 recruiting cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.